Restricted, Non-Sensitive



Market Access in MedTech

Course Director: Anh Bourcet (Nguyen), PhD

Hwee Lin Wee

Saw Swee Hock School of Public Health,

National University of Singapore

Programme – Day 1 – Mon 26 Feb 2024

TOPICS	Speakers
Welcome	
What is Market Access?	Anh Bourcet
HTA policies & evolution in APAC	SS Lee, Senior Director for Government Affairs and Market Access, Medtronic North Asia
Deep dive in Australia : Advocacy strategy to unlock access & funding	Michael Nobes Director, Market Access Abbott, Diabetes
Deep dive in Japan : Market Access strategy	Anh Bourcet
Group case work preparation	Anh Bourcet
Conclusion	

Programme – Day 2 – Tue 27 Feb 2024

TOPICS	Speakers
Recap Day 1	
How to develop a Market Access Strategy for MedTech?	Anh Bourcet
Deep Dive in China - Market Access Strategy in a complex market	Edmund Shi Director, Market Access Head China, Johnson & Johnson MedTech
Policy Shaping & stakeholder engagement	Jamie Kebely Vice President for Asia-Pacific & Japan Government Affairs, Siemens Healthineers
Framework for Value Proposition How to differentiate your technology?	Anh Bourcet
Is Market Access for Medical Devices different from Pharmaceuticals?	TBC
Group case work	
Conclusion	

Programme – Day 3 – Wed 28 Feb 2024

TOPICS	Speakers
Recap Day 2	
How to develop an Evidence Generation Strategy for Market Access ?	TBC
Demonstrating the economic value: key considerations in modelling for MedTech	Hwee-Lin Wee, Associate Professor, Saw Swee Hock School of Public Health, NUS
HTA in ASEAN: understanding what healthcare payers care about	Dr Yot Teerawattananon Co-Director MIDAS (Medical Innovation Development and Assessment Support), Visiting Professor NUS (National University of Singapore), Founder HITAP (Health Intervention and Technology Assessment Program)
Localising your Value Dossier - Pitfalls & Learnings from MEA	Lavni Varyani Founding Partner, Pharma Business Partners
Group case work	
Conclusion	

Programme – Day 4 – Thu 29 Feb 2024

TOPICS	Speakers
Recap Day 3	
Advancing value-based pricing and procurement for a more value based healthcare (VBHC)	Arif Fahim Director Asia-Pacific, Health Economics & Reimbursement, Abbott Medical Devices
Korea: How to develop a comprehensive Market Access strategy in a developed HTA market	Sungwon Jung Director, Gov Affairs & Market Access, Baxter Korea
Reimbursement of Diagnostics : experience from the field in KR, JP, TW	Roche Diagnostics: Harry Peng (Taiwan) Norihisa Yamamoto (Japan) TBC
Digital Health Value Assessment and Reimbursement	Anh Bourcet
Group case work	
Conclusion	

Programme – Day 5 – Fri 1 Mar 2024

TOPICS	Speakers
Recap Day 4	
Market Access strategy for Niche Innovations	Alice Chu Senior Director, Market Access & Medical Affairs APAC, Glaukos
Group case presentation	Jury: Arif Fahim, Nordin Charafi, Anh Bourcet
Precision Medicine: towards an integrated Diagnostics & Treatment Access strategy ?	Nordin Charafi Director, Market Access, Asia Middle East & Africa, Illumina
Funding in Public Health	Global Fund (TBC)
Learnings & week in review	
Conclusion	